FDA Clears Blood Test To Detect Signs Of Alzheimer's Disease
.jpg?h=5b647302&itok=bJrTOor2)
The short version
- The Food and Drug Administration cleared a blood test known as Elecsys pTau-217 for people aged at least 55 who have shown signs of, or have been complaining of…
- The test, which can be used by primary care doctors and specialists, detects a biomarker called plasma phosphorylated tau 217.
- In a study that ran from 2004 to 2025 and was published in JAMA, researchers found that higher levels of the biomarker were associated with an increased risk of progression to…
- As Zachary Stieber reports via The Epoch Times , the FDA has previously approved several other tests for Alzheimer's…
- Roche said its test is the first to measure a single biomarker.
The story
Federal regulators have cleared a blood test aimed at detecting signs of Alzheimer's disease.
The Food and Drug Administration cleared a blood test known as Elecsys pTau-217 for people aged at least 55 who have shown signs of, or have been complaining of, cognitive decline, Roche announced on Aug. 24.
The test, which can be used by primary care doctors and specialists, detects a biomarker called plasma phosphorylated tau 217. In a study that ran from 2004 to 2025 and was published in JAMA, researchers found that higher levels of the biomarker were associated with an increased risk of progression to cognitive impairment.
As Zachary Stieber reports via The Epoch Times, the FDA has previously approved several other tests for Alzheimer's, beginning in 2025 with a test from Fujirebio Diagnostics that measures both pTau217 and another protein. Roche said its test is the first to measure a single biomarker.
"Elecsys pTau217 has the potential to transform how Alzheimer's is assessed across primary and specialty care," Dan Malarek, president and CEO of Roche Diagnostics North America, said in a statement.
"This kind of innovation can help bring diagnostic evaluation closer to patients and give clinicians greater confidence in determining the right step in their care."
Alzheimer's is a brain disorder that destroys a person's memory and thinking skills over time. People with the disease gradually become unable to perform tasks such as eating and walking. Many people begin experiencing symptoms such as memory difficulties between the ages of 60 and 70.
The Alzheimer's Association and other groups have welcomed the tests as a less invasive option than other methods, such as testing of cerebrospinal fluid.
"Each FDA clearance gives clinicians another validated option to work with when evaluating patients showing signs of cognitive impairment," Maria C. Carrillo, the association's chief science officer and medical affairs lead, said in a statement.
"That's real progress for a field that, for decades, had far too few tools to offer."
Dr. Carole Ho, executive vice president and president of Lilly Neuroscience, which helped develop the test, said in a statement that "for millions of families navigating the uncertainty of Alzheimer's disease, a timely diagnosis is the first and most critical step toward meaningful care."
Labcorp and Quest Diagnostics said they will carry the new test.
Once ordered by a doctor, patients can have their blood drawn for the test in a doctor's office, a Labcorp service center, or a Quest center.
Powered by Gab AI
The Story At A Glance
Open the full breakdown on gab.ai
- • The FDA cleared Roche’s Elecsys pTau217 blood test to detect Alzheimer's biomarkers in adults aged 55 and older.
- • This single-biomarker test offers a less invasive alternative to cerebrospinal fluid testing or brain imaging.
- • Labcorp and Quest Diagnostics will provide the test to facilitate earlier clinical evaluation.
Alzheimer's disease causes progressive cognitive decline and loss of physical autonomy. For decades, clinicians lacked efficient, non-invasive tools to identify the amyloid pathology associated with the disease.
Christian Perspective
Early diagnosis allows families to better prepare for the stewardship of elderly members who are losing their cognitive faculties. We must view the aging process through the lens of honoring our elders and providing them with dignity as they face mental decline. This medical advancement can assist in the Christian duty of caring for the vulnerable within the family unit.
Implications
The ability to detect cognitive decline earlier supports the stability of the traditional patriarchal family by allowing for better long-term planning and caregiving. It provides a way to protect the sanctity of the home by managing the needs of the elderly before a crisis occurs. However, we must ensure these diagnostic tools are used to support life rather than as a pretext for devaluing those with diminished mental capacity.
Broader Trends
The expansion of diagnostic testing reflects a growing reliance on centralized medical bureaucracies and corporate pharmaceutical interests. As these technologies become more prevalent, we must remain vigilant against the potential for medical overreach or the use of data to marginalize the elderly. This trend highlights the ongoing tension between technological progress and the preservation of individual and familial autonomy.
Takeaway
Use these medical advancements to strengthen the family's ability to care for its own members. Prioritize the preservation of dignity and the protection of the elderly through proactive, faith-based caregiving. Maintain a healthy skepticism of how large medical corporations might use diagnostic data to influence social policy.
Want to join the conversation about this story?
Join our community at Gab.com→
Gab AI
The one AI they can't control. Our exclusive AI model trained to uphold Christian values and traditional principles in every interaction.
